2026年11月4日星期三
M
Weltübersicht
Globale Kurznachrichten
Singapore's Insignia Ventures backs rural Japan for Davos-inspired academy— 日经 Nikkei AsiaThe great yen rebalancing— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaNorth Korea leans on China and Russia to drive 3% economic growth— 日经 Nikkei AsiaJapan's IHI wins key role in Westinghouse's new Poland nuclear plant— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaSingapore's Insignia Ventures backs rural Japan for Davos-inspired academy— 日经 Nikkei AsiaThe great yen rebalancing— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaNorth Korea leans on China and Russia to drive 3% economic growth— 日经 Nikkei AsiaJapan's IHI wins key role in Westinghouse's new Poland nuclear plant— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Quelle Nature 医学研究Vor 6 Tagen
Inhaltszusammenfassung

Diese Website bietet nur Titel- und Zusammenfassungsindexe. Der vollständige Inhalt und das Urheberrecht liegen beim ursprünglichen Herausgeber. Bitte klicken Sie auf den Original-Link, um ihn zu lesen.

Zum Originaltext
Zugehöriger Kanal
Gesundheit
Zugehörige Region
Globale Perspektive
Originalsprache
English
Eintragsnummer
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · Weltübersicht